Table 1.

YAP/TAZ expression and functional relevance in human pancreatic cancers.

Reference	Number	Target	Location	Positive ratio	Outcomes
Diep et al. (65)
	64	YAP1	Primary	77%	Not available
Yang et al. (66)
	38	YAP	Primary	61%	Not available
	25	YAP	Metastatic site	72%	Not available
Xie et al. (67)
	57	TAZ	Primary	82%*	Not available
Salcedo Allende et al. (68)
	64	YAP1	Primary	90.62%	Poor OS
Rozengurt et al. (69)**
	176	YAP mRNA	Primary	20%	Poor OS
Zhou et al. (70)***
	176	YAP1 mRNA	Primary	50%	Poor OS

*Weak, moderate, and strong expression of TAZ were identified as positive.

**A published interactive open-access database (www.proteinatlas.org/pathology) was used.

***The cohort of The Cancer Genome Atlas (TCGA) was used.

OS, overall survival.